Chronic Thromboembolic Pulmonary Hypertension Drug Treatment
https://doi.org/10.18087/cardio.2024.12.n2784
Abstract
The main treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) is radical surgery, pulmonary thromboendarterectomy (PEA). However, about 40% of patients with CTEPH are inoperable due to distal pulmonary vascular lesions or the severity of hemodynamic disorders. Almost 30% of patients with CTEPH experience persistent or recurrent pulmonary hypertension after surgery, that requires a drug treatment with PAH-specific drugs. This review presents current data on the use of targeted therapy in patients with CTEPH. The review addresses the place, indications, and the evidence base for using the main groups of specific drugs, including stimulators of soluble guanylate cyclase, phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, and prostacyclin analogues.
Supporting agencies: No conflict of interest is reported.
About the Authors
S. N. Ivanov
Meshalkin National Medical Research Center
Russian Federation
Russian Federation
Pediatric cardiologist Consultative and diagnostic department No. 1
Novosibirsk, Russia
A. M. Chernyavsky
Meshalkin National Medical Research Center
Russian Federation
Russian Federation
Director General, Corresponding Member of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor
Novosibirsk, Russia
A. G. Edemsky
Meshalkin National Medical Research Center
Russian Federation
Russian Federation
Cardiovascular surgeon Cardiac surgery department No. 2
PhD
Novosibirsk, Russia
O. Ya. Vasiltseva
Meshalkin National Medical Research Center
Russian Federation
Russian Federation
Leading researcher Research Department of Aortic Surgery, Coronary and Peripheral Arteries of the Institute of Circulatory Pathology
Doctor of Medical Sciences.
Novosibirsk, Russia
References
1. Ende-Verhaar YM, Cannegieter SC, Vonk Noordegraaf A, Delcroix M, Pruszczyk P, Mairuhu ATA et al. Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. European Respiratory Journal. 2017;49(2):1601792. DOI: 10.1183/13993003.01792-2016
2. Chazova I.E., Martynyuk T.V., Shmalts A.A., Gramovich V.V., Danilov N.M., Veselova T.N. et al. Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension (2023). Eurasian heart journal. 2024;1(46):6–85. DOI: 10.38109/2225-1685-2024-1-6-85
3. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618–731. DOI: 10.1093/eurheartj/ehac237
4. Avdeev S.N., Barbarash O.L., Valieva Z.S., Volkov A.V., Veselova T.N., Galyavich A.S. et al. 2024 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2024;29(11):1–81. DOI: 10.15829/1560-4071-2024-6161
5. Kim NH, D’Armini AM, Delcroix M, Jaïs X, Jevnikar M, Madani MM et al. Chronic thromboembolic pulmonary disease. European Respiratory Journal. 2024;64(4):2401294. DOI: 10.1183/13993003.01294-2024
6. Freed DH, Thomson BM, Berman M, Tsui SSL, Dunning J, Sheares KK et al. Survival after pulmonary thromboendarterectomy: Effect of residual pulmonary hypertension. The Journal of Thoracic and Cardiovascular Surgery. 2011;141(2):383–7. DOI: 10.1016/j.jtcvs.2009.12.056
7. Lang IM. Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options. European Respiratory Review. 2009;18(111):24–8. DOI: 10.1183/09059180.00011110
8. Evgenov OV, Pacher P, Schmidt PM, Haskó G, Schmidt HHHW, Stasch J-P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nature Reviews Drug Discovery. 2006;5(9):755–68. DOI: 10.1038/nrd2038
9. Ghofrani H-A, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH et al. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension. New England Journal of Medicine. 2013;369(4):319–29. DOI: 10.1056/NEJMoa1209657
10. Simonneau G, D’Armini AM, Ghofrani H-A, Grimminger F, Hoeper MM, Jansa P et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). European Respiratory Journal. 2015;45(5):1293–302. DOI: 10.1183/09031936.00087114
11. Ghofrani H-A, Gomez Sanchez M-A, Humbert M, Pittrow D, Simonneau G, Gall H et al. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine. 2021;178:106220. DOI: 10.1016/j.rmed.2020.106220
12. Benza RL, Langleben D, Hemnes AR, Vonk Noordegraaf A, Rosenkranz S, Thenappan T et al. Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. European Respiratory Review. 2022;31(166):220061. DOI: 10.1183/16000617.0061-2022
13. Marra AM, Halank M, Benjamin N, Bossone E, Cittadini A, Eichstaedt CA et al. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respiratory Research. 2018;19(1):258. DOI: 10.1186/s12931-018-0957-y
14. Barnikel M, Kneidinger N, Arnold P, Waelde A, Behr J, Milger K. Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities. Journal of Clinical Medicine. 2022;11(4):1084. DOI: 10.3390/jcm11041084
15. Mahmud E, Patel M, Ang L, Poch D. Advances in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Pulmonary Circulation. 2021;11(2):1–9. DOI: 10.1177/20458940211007385
16. Kataoka M, Inami T, Kawakami T, Fukuda K, Satoh T. Balloon Pulmonary Angioplasty (Percutaneous Transluminal Pulmonary Angioplasty) for Chronic Thromboembolic Pulmonary Hypertension. JACC: Cardiovascular Interventions. 2019;12(14):1382–8. DOI: 10.1016/j.jcin.2019.01.237
17. Delcroix M, Torbicki A, Gopalan D, Sitbon O, Klok FA, Lang I et al. ERS statement on chronic thromboembolic pulmonary hypertension. European Respiratory Journal. 2021;57(6):2002828. DOI: 10.1183/13993003.02828-2020
18. Delcroix M, De Perrot M, Jaïs X, Jenkins DP, Lang IM, Matsubara H et al. Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management. The Lancet Respiratory Medicine. 2023;11(9):836–50. DOI: 10.1016/S2213-2600(23)00292-8
19. Jaïs X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. The Lancet Respiratory Medicine. 2022;10(10):961–71. DOI: 10.1016/S2213-2600(22)00214-4
20. General characteristics of the drug Adempas® ЛП-№(000764)-(РГ-RU). Av. at: https://pharma.bayer.ru/files/Adempas.pdf.
21. Olschewski H, Simonneau G, Galiè N, Higenbottam T, Naeije R, Rubin LJ et al. Inhaled Iloprost for Severe Pulmonary Hypertension. New England Journal of Medicine. 2002;347(5):322–9. DOI: 10.1056/NEJMoa020204
22. Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. European Respiratory Review. 2009;18(111):29–34. DOI: 10.1183/09059180.00011111
23. Instructions for the medical use of the drug Ventavis® (ЛСР-005775/10). Av. at: https://pharma.bayer.ru/sites/g/files/vrxlpx3916/files/2021-04/Ventavis.pdf?
24. Jaïs X, D’Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA et al. Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of the American College of Cardiology. 2008;52(25):2127–34. DOI: 10.1016/j.jacc.2008.08.059
25. Ghofrani H-A, Simonneau G, D’Armini AM, Fedullo P, Howard LS, Jaïs X et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. The Lancet Respiratory Medicine. 2024;12(4):e21–30. DOI: 10.1016/S2213-2600(24)00027-4
26. Escribano‐Subias P, Bendjenana H, Curtis PS, Lang I, Noordegraaf AV. Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Pulmonary Circulation. 2019;9(2):1–3. DOI: 10.1177/2045894019846433
27. Actelion. A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/ Recurrent Chronic Thromboembolic Pulmonary Hypertension (MACiTEPH). NCT04271475. Av. at: https://clinicaltrials.gov/study/NCT04271475.2024.
28. Suntharalingam J, Treacy CM, Doughty NJ, Goldsmith K, Soon E, Toshner MR et al. Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension. Chest. 2008;134(2):229–36. DOI: 10.1378/chest.07-2681
29. Kim NH, Channick R, Delcroix M, Madani M, Pepke-Zaba J, Borissoff JI et al. Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial). European Respiratory Journal. 2024;64(4):2400193. DOI: 10.1183/13993003.00193-2024
30. Actelion. Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (MERIT-2). NCT02060721. Av. at: https://clinicaltrials.gov/study/NCT02060721.2023.
31. Grant SM, Goa KL. Iloprost: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Peripheral Vascular Disease, Myocardial Ischaemia and Extracorporeal Circulation Procedures. Drugs. 1992;43(6):889–924. DOI: 10.2165/00003495-199243060-00008
32. Olschewski H, Rohde B, Behr J, Ewert R, Gessler T, Ghofrani HA et al. Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension. Chest. 2003;124(4):1294–304. DOI: 10.1378/chest.124.4.1294
33. Hemnes AR, Champion HC. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. Expert Review of Cardiovascular Therapy. 2006;4(3):293–300. DOI: 10.1586/14779072.4.3.293
34. Ghofrani HA, Schermuly RT, Rose F, Wiedemann R, Kohstall MG, Kreckel A et al. Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine. 2003;167(8):1139–41. DOI: 10.1164/rccm.200210-1157BC
35. Reichenberger F, Voswinckel R, Enke B, Rutsch M, El Fechtali E, Schmehl T et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. European Respiratory Journal. 2007;30(5):922–7. DOI: 10.1183/09031936.00039007
36. Delcroix M, Pepke-Zaba J, D’Armini AM, Fadel E, Guth S, Hoole SP et al. Worldwide CTEPH Registry: Long-Term Outcomes With Pulmonary Endarterectomy, Balloon Pulmonary Angioplasty, and Medical Therapy. Circulation. 2024;150(17):1354–65. DOI: 10.1161/CIRCULATIONAHA.124.068610
37. Öngen HG, Akdeniz B, Düzenli MA, Chernyavsky A, Dabar G, Idrees M et al. Diagnosis and Treatment Patterns of Chronic Thromboembolic Pulmonary Hypertension in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia: A Registry Study. Drugs - Real World Outcomes. 2024;11(1):149–65. DOI: 10.1007/s40801-023-00407-w
38. General characteristics of the drug Revatsio® ЛП-№(000898)-(РГ-RU). Av. at: https://www.vidal.ru/drugs/revatio__30058?
39. Summary of product characteristics. Revatio 20 mg film-coated tablets. Av. at: https://www.ema.europa.eu/en/documents/product-information/revatio-epar-product-information_en.pdf.
40. Darocha S, Banaszkiewicz M, Pietrasik A, Piłka M, Florczyk M, Wieteska M et al. Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics. International Journal of Cardiology. 2018;269:283–8. DOI: 10.1016/j.ijcard.2018.07.015
41. Iglarz M, Steiner P, Wanner D, Rey M, Hess P, Clozel M. Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors: Journal of Cardiovascular Pharmacology. 2015;66(4):332–7. DOI: 10.1097/FJC.0000000000000283
42. Correale M, Ferraretti A, Monaco I, Grazioli D, Di Biase M, Brunetti ND. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? Vascular Health and Risk Management. 2018;14:253–64. DOI: 10.2147/VHRM.S133921
43. Confalonieri M, Kodric M, Longo C, Vassallo FG. Bosentan for chronic thromboembolic pulmonary hypertension. Expert Review of Cardiovascular Therapy. 2009;7(12):1503–12. DOI: 10.1586/erc.09.148
44. Chen X, Zhai Z, Huang K, Xie W, Wan J, Wang C. Bosentan therapy for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: A systemic review and meta‐analysis. The Clinical Respiratory Journal. 2018;12(6):2065–74. DOI: 10.1111/crj.12774
45. Duggan ST, Keam SJ, Burness CB. Selexipag: A Review in Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs. 2017;17(1):73–80. DOI: 10.1007/s40256-016-0209-9
Review
For citations:
Ivanov S.N., Chernyavsky A.M., Edemsky A.G., Vasiltseva O.Ya. Chronic Thromboembolic Pulmonary Hypertension Drug Treatment. Kardiologiia. 2024;64(12):77-85. (In Russ.) https://doi.org/10.18087/cardio.2024.12.n2784
Views:
682
Email this article 
Post a Comment 
